Latest news with #EHR
Business Insider
8 hours ago
- Business
- Business Insider
Tempus AI announces expansion of Tempus One
Tempus AI (TEM) announced the expansion of Tempus One-its generative AI clinical assistant-with direct integration into electronic health record, EHR, systems. By integrating AI at every point of the clinical care process, the expanded capabilities of Tempus One offer physicians in oncology and beyond more support in treatment decisions. Tempus One is uniquely positioned to offer these new features given the company's depth and scale of EHR integrations with providers across the U.S. Confident Investing Starts Here:
Business Wire
21 hours ago
- Business
- Business Wire
Introducing Tempus One in the EHR with Integrated Guidelines
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the expansion of Tempus One—its generative AI clinical assistant—with direct integration into electronic health record (EHR) systems. By integrating AI at every point of the clinical care process, the expanded capabilities of Tempus One offer physicians in oncology and beyond more support in treatment decisions. Tempus One is uniquely positioned to offer these new features given the company's depth and scale of EHR integrations with providers across the U.S. Tempus has developed an integrated architecture that captures real-time clinical, molecular and imaging data from millions of patients and makes that data easily digestible and useful for clinicians and care teams. Through Tempus One, physicians can gain AI-enabled insights that transform how they interact with patient data, streamlining complex treatment decisions and reducing time spent on administrative tasks. New capabilities in the latest iteration of Tempus One: Integration of ASCO Guidelines: Tempus One is integrating ASCO's clinical practice guidelines into the platform to equip physicians with the latest guidelines and information to guide personalized patient care. Oncologists are now able to easily access ASCO's guidelines, which provide evidence-based, treatment and care recommendations. Clinical Workflow Assistance: Tempus One has a suite of new features, designed to help physicians at every step with tailored insights and reduce the burden of administrative tasks. Pre-Appointment Preparation: Tempus One summarizes patient history, treatment journey, and recent biomarker status, ensuring physicians are well-prepared for appointments. Real-Time Support During Appointments: Tempus One can transcribe conversations, take intelligent notes, and highlight key information, allowing physicians to focus on patient care. Post-Appointment Assistance: Tempus One supports documentation tasks, treatment planning based on updated guidelines and research, prepares prior authorizations, and facilitates clinical trial matching. Agent Builder: Over the past several months, Tempus has used its Agent Builder GenAI tool internally to develop and deploy more than 1,000 AI agents. Now, Tempus is extending access to this toolset to a select group of partner providers, collaborating with them to create and test custom GenAI solutions tailored to their unique needs and preferences. The agents are designed to create efficiencies and streamline workflows, such as generating custom patient overviews to accelerate pre-charting or generating notes from conversations with patients to be added into their EHR records. These custom agents can be developed in collaboration with dedicated Tempus team members. By referencing institutions' standard operating procedures and data repositories, these agents can be seamlessly integrated into existing workflows through One. 'As healthcare faces rising costs and growing complexity, no group bears the burden more heavily than physicians and care teams,' said Ryan Fukushima, Chief Operating Officer at Tempus. 'This evolution of Tempus One represents a meaningful shift from a world where clinicians spend countless hours searching for answers and documenting care, to one where AI rapidly connects the dots across fragmented systems to deliver actionable insights in real time.' To learn more about Tempus One, view a video here and visit the website here. About Tempus Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit Forward Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the 'Securities Act'), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus' industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the expected outcomes and benefits of Tempus One and its capabilities for customers. In some cases, you can identify forward-looking statements because they contain words such as 'anticipate,' 'believe,' 'contemplate,' 'continue,' 'could,' 'estimate,' 'expect,' 'going to,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' or 'would' or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release. You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus' business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: Tempus' financial performance; the ability to attract and retain customers and partners; managing Tempus' growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus' intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled 'Risk Factors' in Tempus' Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission ('SEC') on February 24, 2025, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.
Medscape
4 days ago
- General
- Medscape
Geriatric CDS Tool Boosts Safe Prescribing in the ED
The use of an electronic health record (EHR)–based clinical decision support (CDS) system in emergency departments (EDs) increased adherence to geriatric prescribing recommendations for potentially inappropriate medications (PIMs). METHODOLOGY: In this retrospective study, the researchers analyzed 6745 ED orders during 5814 patient encounters (median age, 72 years; approximately 70% White and 22.7% Black) and 1440 discharge prescriptions for PIMs in adults aged 65 years or older between August and December 2021. In October 2021, a geriatric CDS system was implemented into the EHR, which provided dosing recommendations and suggested alternative medications for 12 high-risk PIMs. The primary outcome was adherence to CDS recommendations. Secondary outcomes included the use of the CDS panel and adherence rates by medication type. TAKEAWAY: Following the implementation of CDS, the proportion of targeted PIMs adherent to geriatric recommendations increased from 52% to 71% for ED orders and from 0.5% to 31.7% for discharge prescriptions. Utilization of the geriatric CDS order panel reached 62.1% for ED orders and 36.7% for discharge prescriptions. Among orders placed through the geriatric CDS panels, 90% of ED orders and 80.4% of discharge prescriptions adhered to geriatric CDS recommendations. Adherence to geriatric CDS improved for most ED orders, except for a few drugs such as diphenhydramine, indomethacin, oral and intravenous ketorolac, and oral lorazepam. IN PRACTICE: "Geriatric clinical decision support implemented in the ED for targeted potentially inappropriate medications significantly increased the proportion of ED orders and discharge prescriptions adherent to geriatric drug therapy recommendations," the authors wrote. "As the volume of older patients in the ED increases, electronic health record–based clinical decision support can allow for care that is both better tailored and safer for this vulnerable population," they added. SOURCE: The study was led by Gina A. Elder, PharmD, Cleveland Clinic, Cleveland. It was published online on May 13 in Academic Emergency Medicine . LIMITATIONS: Prescriber behavior changes and shared decision-making with patients could have influenced the findings. Data on important patient covariates such as ethnicity, preexisting dementia history, primary language, and rurality were not collected. Differences in patient volumes and site-level variations were not considered. DISCLOSURES: The authors did not report any funding information and reported no relevant conflicts of interest.
Business Wire
4 days ago
- Business
- Business Wire
Trinity Life Sciences Expands Data Partnership Network to Revolutionize Commercialization in Community Oncology
BUSINESS WIRE)-- Trinity Life Sciences, a leader in advisory, insights and analytics for the life sciences industries, announces a strategic collaboration with Ontada, a McKesson business and leader in community oncology real-world data, clinical education and point-of-care technologies. This relationship will provide life sciences companies with real-time, actionable intelligence and critical insights to drive strategic decisions both pre- and post-product launch. Together, the alliance harnesses Trinity's innovative commercial analytics methods and expertise with Ontada's iKnowMed ®, their proprietary electronic health record (EHR) with unique, deep and multi-dimensional oncology data, to rapidly uncover novel commercial insights. These insights can be leveraged to drive smarter decisions and better outcomes, ultimately enabling a transformation in the way life sciences companies make commercial decisions. Through deep understanding of the community oncology patients and providers, the collaborative solutions: - provide more powerful patient journeys and provider segmentation, - allow for increased speed and accuracy in forecasting, - and drive enhanced customer engagement and targeting. 'Understanding community oncology presents a particular challenge for commercial teams as they work to develop strategies and deploy resources to maximize adoption of life-saving therapies,' said Leslie Orne, President and CEO of Trinity Life Sciences. 'Ontada's data, coupled with Trinity's analytical services, allows the extraction of deeper, more actionable insights and powers more impactful commercial decision-making that will help to optimize patient outcomes.' Trinity's oncology expertise and depth across areas such as forecasting, real-world analytics and primary market research (PMR) allows for distinctive, AI-enhanced approaches that provide ever-greater insight into key business questions to assess potential outcomes. Trinity offers innovative solutions built for life sciences' unique needs, scaling transformational AI and tech-enabled programs across functions with a focus on customer engagement, launch, medical affairs and GenAI. 'The need for rapid insights in cancer care has never been greater. Ontada's collaboration with Trinity demonstrates our commitment to delivering faster answers to critical questions. By connecting Trinity's robust analytics with Ontada's nuanced and unique data sets, we can provide deeper, more actionable insights for our life science partners,' said Christine Davis, President of Ontada. 'Speed is crucial not only to our life science partners but also for cancer patients, who can benefit greatly from a better understanding of precision therapies.' Ontada's real-world data provides comprehensive insights throughout the patient journey and a unique view of community cancer care. It represents data from more than 2.4 million patient records across over 80 tumor types from The US Oncology Network and Onmark practices. Ontada's iKnowMed ® is an award winning EHR used by more than 2,400 oncology community-based providers across the United States, dedicated to advancing local cancer care and better patient outcomes. To learn more about this collaboration, visit Trinity Life Sciences and Ontada (at Ontada's booth 35093) at ASCO. About Trinity Life Sciences With almost 30 years of expertise, a best-in-the-business team and unrivaled access to data and analytics, Trinity Life Sciences is a modern partner to companies in the life sciences industry. Trinity combines strategy, insights and analytics to help life science executives with clinical and commercial decision-making. Ultimately, we know that every decision our clients make impacts a life, and when we help our clients achieve their goals, the world benefits. To learn more about how Trinity is elevating the industry and driving evidence to action, visit
Associated Press
5 days ago
- Business
- Associated Press
Healthcare Triangle Secures Major Health System Contracts and Expands AI-Powered EHR Services Nationwide
New Multi-year Wins, Platform Innovation, and AI-driven Growth Strategy Position HCTI for Sustained Growth PLEASANTON, CALIF. - May 28, 2025 ( NEWMEDIAWIRE ) - Healthcare Triangle, Inc. (Nasdaq: HCTI) ('HCTI' or the 'Company'), a leader in digital transformation solutions including managed services, cloud enablement, and data analytics for the healthcare and life sciences industries – today announced approximately $1.0 million of new multi-year strategic contracts wins. These include major agreements with a top-tier university medical system and the largest hospital system on the East Coast. In addition, HCTI is significantly expanding its AI and EHR integration services, reinforcing its position as a trusted innovation partner to health systems nationwide. 'These strategic wins reflect our ability to deliver enterprise-scale transformation with speed and precision,' said Sujatha Ramesh, Chief Operating Officer of Healthcare Triangle. 'We're enabling digital maturity, operational efficiency, and cost-effective care delivery - firmly positioning HCTI as a mission-critical partner, not just a service provider.' Aligned with its innovation roadmap, HCTI has also expanded its portfolio with an AI-powered a next-generation AI medical document automation platform that transforms faxes, scanned forms, and unstructured clinical text into structured, actionable data - seamlessly integrating with the electronic health record (EHR). Existing healthcare systems have realized significant benefits by automating their document management processes through The solution has also facilitated the transformation of unstructured clinical text into structured, actionable data - seamlessly integrating with electronic health records (EHR) to enhance clinical decision-making and operational efficiency 'These wins and platform advancements are accelerating our shift to a recurring revenue model,' added David Ayanoglou, Chief Financial Officer of HCTI. 'We're delivering scalable, AI-powered solutions that improve margins, expand our footprint, and increase enterprise value. HCTI is well-positioned for long-term growth and profitability.' Further strengthening its community focus, HCTI is exploring high-impact EPIC workflow integrations tailored to community health system deployments. These efforts aim to enhance clinical efficiency, streamline onboarding, and bring enterprise-grade performance to underserved and regional networks - delivering scalable solutions at lower cost. With a growing portfolio of strategic contracts, breakthrough AI platforms, and an expanding presence across enterprise and community health systems, HCTI is charting a clear path towards sustainable, technology-driven growth. The Company remains focused on delivering innovation at scale and unlocking long-term value for clients, partners, and shareholders. HCTI maintains strategic partnerships with leading public cloud providers - Amazon Web Services (AWS), Google Cloud Platform (GCP), and Microsoft Azure. About Healthcare Triangle Healthcare Triangle, Inc. based in Pleasanton, California, reinforces healthcare progress through breakthrough technology and extensive industry knowledge and expertise. We support healthcare including hospitals and health systems, payers, and pharma/life sciences organizations in their effort to improve health outcomes through better utilization of the data and information technologies that they rely on. Healthcare Triangle achieves HITRUST Certification for Cloud and Data Platform (CaDP), marketed as CloudEz(TM) and DataEz(TM). HITRUST Risk-based, 2-year (r2) Certified status demonstrates to our clients the highest standards for data protection and information security. Healthcare Triangle enables the adoption of new technologies, data enlightenment, business agility, and response to immediate business needs and competitive threats. The highly regulated healthcare and life sciences industries rely on Healthcare Triangle for expertise in digital transformation encompassing the cloud, security and compliance, data lifecycle management, healthcare interoperability, and clinical and business performance optimization. Forward-Looking Statements and Safe Harbor Notice All statements other than statements of historical facts included in this press release are 'forward-looking statements' (as defined in the Private Securities Litigation Reform Act of 1995), and include, among others, statements regarding the consummation of the private placement, satisfaction of the customary closing conditions of the private placement and the use of the proceeds therefrom. Such forward-looking statements include our expectations and those statements that use forward-looking words such as 'projected,' 'expect,' 'possibility' and 'anticipate.' The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties, and assumptions, including market and other conditions. Actual results could differ materially from current projections or implied results. Investors should read the risk factors set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, on file with the Securities Exchange Commission (the 'SEC') and in previous filings, subsequent filings and future periodic reports filed with the SEC. All the Company's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. Investors: 1-800-617-9550 [email protected]
